Table 3.
Study (year) | Histological grade | FDG-PET imaging system(s) | FDG dose | Time between FDG administration and scanning | Time between last therapy cycle and FDG-PET (range) | Interpreters | Baseline scan available (no.) | Follow-up examinations to determine end of PFS | Definition of end of PFS |
---|---|---|---|---|---|---|---|---|---|
Lu et al. [6] (2014) | 1-3A | Stand-alone PET (n = 15) or hybrid PET/CT (n = 42) | 5.14 MBq/kg | 60 min | NR | Experienced PET physicians | Yes (55/57 cases) | NR | Relapse or aggressive transformation |
Luminari et al. [7] (2014) | NR | Hybrid PET/CT | NR | NR | 36 daysa (10–92) | Local nuclear medicine physician scan report | Yes (155/202 cases) | NR | Progression, relapse, or death from any cause |
Zinzani et al. [8] (2013) | Grade 1-3A | NR | NR | NR | NR | Local nuclear medicine physician scan report | Yes | CT every 6 months for the first 2 years, annual imaging studies with CT or FDG-PET/CT up to 7 years | Progression or death from any cause |
Dupuis et al. [9] (2012) | 1-3A | NR | 3.5–8 MBq/kg | 60 min | NR | Central review by 3 experienced nuclear medicine physicians | Yes (all) | Clinical examination every 3 months and CT scan every 6 months during the first 2 years | First documented evidence of progressive disease, relapse, or death resulting from any cause |
Trotman et al. [10] (2011) | NR | Hybrid PET/CT | NR | NR | 64 daysa (9–124) | Local nuclear medicine physician scan report | NR | Clinical examination every 3 months and CT scans every 6 months for 3 years | Progression/relapse (on the basis of the investigator's assessment) or death from any cause |
Le Dortz et al. [11] (2010) | 1-3a | Hybrid PET/CT | 5 MBq/kg | 60 min | NR | Two nuclear medicine specialists | Yes (all) | NR | Progression, relapse or second-line therapy |
Bishu et al. [12] (2007) | 1 or 2 | Stand-alone PET or hybrid PET/CT | 370–740 MBq | 60 min | NR | Experienced nuclear radiologists | Yes (all) | Conventional methods every 3–6 months for 1 year, every 6–12 months for 2 years, FDG-PET examination every 3–12 months | Histologic, clinical or radiographic evidence of disease progression |
Zinzani et al. [13] (2007) | 1 or 2 | Stand-alone PET | 370 MBq | 70–90 min | Approximately 30 days | Three experienced readers | Yes | CT and FDG-PET were performed every 6 months for the first 2 years and then every 12 months | Progression or relapse |
NR not reported, PFS progression-free survival
aMedian